✦ LIBER ✦

A Cost-Effectiveness Analysis of Axitinib and Sorafenib for 2nd Line Treatment of Advanced Renal Cell Carcinoma After Failure of Cytokines in the United States

✍ Scribed by Stillman, I.O.; Ambavane, A.; Cislo, P.

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

PCN18 ECONOMIC IMPLICATIONS OF THE FIRST

✍ Topibulpong, N; Tanasanvimon, S; Parinyanitikul, N; Vinayanuwattikun, C; Sriuran 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 68 KB

PCN62 Cost-Effectiveness Analysis of Fir

✍ Nuñez, S.M.; Godoy, J.I.; Cardona, A.F.; Otero, J.M.; Lujan, M.; Lopera, D.; Car 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 60 KB

Cost-Effectiveness And Cost-Utility Anal

✍ Torres Toala, F.G.; Albuja Riofrio, M.F.; Mould, J.F.; Estévez, C. 📂 Article 📅 2013 🏛 John Wiley and Sons 🌐 English ⚖ 72 KB

PCN26 COST-EFFECTIVENESS AND COST-UTILIT

✍ Salinas-Escudero, G; Contreras-Hernandez, I; Mould-Quevedo, J 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 64 KB

PCN13 COST-EFFECTIVENESS ANALYSIS OF FIR

✍ Godoy, JI; Cardona, AF; Caceres, HA; Otero, JM; Lujan, M; Lopera, D; Pacheco, JO 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 64 KB

PCN30 A COST—UTILITY ANALYSIS MODEL FOR

✍ I Contreras-Hernandez; J Mould-Quevedo; G Salinas-Escudero; J Tapia-Valencia; G 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 84 KB